Group II (PPA group) received a neurotoxic dose of PPA (250 mg/kg body weight/day) orally via gavage for 3 days, followed by PBS for 21 days (Abd El-Hady et al
The clinical presentation and progression of NAION manifests through: Sudden, painless monocular vision loss occurring over hours to days, often discovered upon awakening Altitudinal visual field defects affecting either the superior or inferior visual field Visual acuity loss ranging from mild (20/30) to severe (counting fingers or worse) Optic disc edema during the acute phase, progressing to optic atrophy over 4-6 weeks Risk of bilateral involvement, with 15% of patients developing NAION in the second eye within five years No effective treatment to restore vision once damage occurs Permanent disability requiring lifestyle adaptations and assistive technologies The pathophysiology of NAION involves impaired perfusion to the anterior portion of the optic nerve head, though the exact mechanism remains incompletely understood
BHKs 85100 BHKs 60 1,399 1 23 / 250mg C100mg CE - BHKs1C 5
These medications work by mimicking a natural hormone that helps regulate hunger and blood sugar
It's all about what works for you, how you're feeling and what your prescriber recommends
The new science of GLP-1: effects beyond glucose control
